Abstract
The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters impedes effective treatment of EGFR mutant and resistant lung cancer. This review appraises current literature, opportunities, and challenges associated with liquid biopsy and pharmacogenomic (PGx) testing as precision therapy tools in the management of EGFR mutant and resistant lung cancers. Liquid biopsy could play a potential role in selection of precise tyrosine kinase inhibitor (TKI) therapies during different phases of lung cancer treatment. This selection will be based on the driver EGFR mutational status, as well as monitoring the development of potential EGFR mutations arising during or after TKIs treatment, since some of these new mutations may be druggable targets for alternative TKIs. Several studies have identified the utility of liquid biopsy in the identification of EGFR driver and acquired resistance with good sensitivities for various blood-based biomarkers. With a plethora of sequencing technologies and platforms available currently, further evaluations using randomized controlled trials (RCTs) in multicentric, multiethnic and larger patient cohorts could enable optimization of liquid-based assays for the detection of EGFR mutations, and support testing of CYP450 enzymes and drug transporter polymorphisms to guide precise dosing of EGFR TKIs.
Document Type
Review
Publication Date
2-24-2022
Digital Object Identifier (DOI)
https://doi.org/10.1186/s12943-022-01534-8
Repository Citation
Kolesar, Jill M.; Peh, Spencer; Thomas, Levin; Baburaj, Gayathri; Mukherjee, Nayonika; Kantamneni, Raveena; Lewis, Shirley; Pai, Ananth; Udupa, Karthik S.; Kumar An, Naveena; Rangnekar, Vivek M.; and Rao, Mahadev, "Integration of Liquid Biopsy and Pharmacogenomics for Precision Therapy of EGFR Mutant and Resistant Lung Cancers" (2022). Pharmacy Practice and Science Faculty Publications. 75.
https://uknowledge.uky.edu/pps_facpub/75
Additional file 1: Supplementary Table 1. Completed and ongoing trials on liquid biopsy for the detection of EGFR mutant NSCLC.
Included in
Oncology Commons, Pharmacy and Pharmaceutical Sciences Commons, Radiation Medicine Commons
Notes/Citation Information
Published in Molecular Cancer, v. 21, article no. 61.
© 2022 The Author(s)
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.